Vascular access by catheterisation is a vital tool in today’s healthcare – allowing blood removal, dialysis, administration of drugs and diagnosis. However, endothelial reaction towards catheterisation and resulting dysfunction often result in spasm and thrombus formation. Such responses cause pain to the patient and procedural complication as well as an increased risk of embolism, thrombosis, heart attack and stroke.1,2
MOFgen products enable the controlled release of the potent vasodilator and thrombus inhibitor nitric oxide from the surface of catheters to relax the artery and discourage thrombus formation. This local delivery avoids potential complications associated with systemic approaches and mimics the natural processes of the healthy endothelium.